Kuehn Law, PLLC is investigating whether certain officers and directors of Summit Therapeutics Inc. breached their fiduciary duties to shareholders through potential self-dealing. This legal probe could lead to damages for shareholders and reforms in corporate governance. Long-term shareholders are encouraged to contact the law firm for a free consultation to explore their rights and possible claims. The investigation highlights concerns about management's integrity and the protection of investor interests at Summit Therapeutics.
Summit Therapeutics reported a wider-than-expected loss and disclosed a 'going concern risk' due to insufficient cash to fund operations for the next year, despite raising over $300 million recently. The company is cutting costs and has $690.7 millio...
Guggenheim has reiterated its Buy rating on Summit Therapeutics despite lowering the price target slightly to $38 from $40, indicating confidence in the stock's upside from its current price of $14.98. The positive outlook follows strong Q2 2026 earn...
Summit Therapeutics has been upgraded from 'Hold' to 'Buy' following the FDA's acceptance of its Biologics License Application (BLA) for ivonescimab combined with chemotherapy to treat EGFR-mutant non-small cell lung cancer (NSCLC). The company's Pha...
